ABSTRACT: Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to improve the prognosis of patients with HF. The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant reductions in mortality and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor. The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk. Although SGLT2 inhibition may have potential application beyond T2D, including HF, the mechanisms responsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood. SGLT2 inhibition promotes natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decreases in blood pressure, arterial stiffness, and afterload as well, thereby improving subendocardial blood flow in patients with HF. SGLT2 inhibition is also associated with preservation of renal function. Based on data from mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now investigating the potential use of SGLT2 inhibition in patients who have HF with and without T2D. Accordingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D. Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease or hypertension. Finally, we provide a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.
W
orldwide, 1% to 2% of the general adult population have heart failure (HF), which is accompanied by reduced quality of life, high morbidity, mortality, and significant financial costs. 1 Existing therapies such as renin angiotensin aldosterone system (RAAS) inhibition, β-blockade, and angiotensin receptor-neprilysin inhibitors reduce hospitalization and mortality risk in patients with HF and reduced ejection fraction (HFrEF). 2 Despite important cardiovascular benefits with the use of these agents, patients still have an increased risk for morbidity and mortality. These therapies also carry the potential for serious adverse effects including hypotension, kidney dysfunction, and electrolyte abnormalities. 2 Identification of novel therapeutic strategies to improve symptoms, reduce mortality, recurrent hospitalization, and acute decompensation is therefore critical to advance outcomes in patients with HF.
Type 2 diabetes mellitus (T2D) is among many comorbidities associated with cardiovascular disease (CVD) that contributes to end-organ damage, and T2D also intensifies the risk for developing HF 3 and HF-related complications, including death. 4 These risks are further compounded in the presence of diabetic nephropathy, highlighting an important interaction between T2D, chronic kidney disease (CKD), and HF. 5 The aims of this review are to summarize experimental and clinical evidence, which support the rationale for the use of antihyperglycemic sodium-glucose cotransport-2 (SGLT2) inhibitor agents in patients with T2D and HF, and to critically appraise whether SGLT2 inhibition may also be applicable in patients with HF without T2D.
HF CURRENT THERAPEUTIC STRATEGIES AND UNMET NEEDS
The 2 major types of HF, broadly categorized based on systolic function are: (1) HFrEF, left ventricular ejection fraction <40%, and (2) HF with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥40%. Mechanistically, HF is accompanied by the activation of several key neurohormonal regulatory systems, including the sympathetic nervous system and the RAAS, and by the dysfunction of endogenous natriuretic mechanisms. 6 Activation of these compensatory pathways initially maintains blood pressure and preserves renal function. Over time, however, chronic neurohormonal activation increases left ventricular afterload and promotes vascular and cardiac remodeling and HF disease progression.
Current standards of care for patients with HFrEF include β-blockers, RAAS inhibitors, angiotensin receptorneprilysin inhibitors, diuretics, and digoxin to suppress neurohormones, reduce volume overload, and improve cardiac contractility. 6, 7 Conventional diuretics only provide symptomatic relief for patients with HF but do not impact mortality (Figure 1 ). In contrast with HFrEF, current HF therapies fail to improve outcomes in patients with HFpEF. 6 Accordingly, HFpEF management focuses on the treatment of comorbidities such as T2D, hypertension, coronary artery disease, and obesity. 8 Despite overall clinical benefits, currently available HF therapies, such as RAAS inhibitors and diuretics, increase the risk of adverse effects because of hypotension, volume depletion, and sympathetic nervous system activation, highlighting the urgent need for safe, novel therapies.
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ANTIHYPERGLYCEMIC AGENTS AND CARDIOVASCULAR SAFETY TRIALS
New insights into HF management have emerged somewhat unexpectedly from trials examining antihyperglycemic agents used in the treatment of T2D. Although metformin and insulin may not impact HF progression, thiazolidinediones are associated with an increased risk of edema and HF. 12 These findings led to the requirement by regulatory agencies for cardiovascular safety studies for all new antihyperglycemic agents. The dipeptidyl-peptidase 4 inhibitors, saxagliptin and alogliptin but not sitagliptin, have also been associated with an increased risk of hospitalization for HF by the US Food and Drug Administration and European Medicines Agency; responsible mechanisms are, however, not currently known. 13, 14 In contrast, liraglutide, a GLP-1 receptor agonist (GLP-1RA), was shown to reduce cardiovascular events by 13%, and also reduced all-cause mortality and nephropathy events in the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), a cardiovascular safety study in patients with T2D at heightened cardiovascular risk 15 ( Figure 2 ). It is important to note that once-daily liraglutide administration did not increase the risk of hospitalization for HF in comparison with placebo, including in the subgroup of patients with preexisting HF after 3.8 years follow-up. 15 The cardioprotective effects associated with liraglutide emerged at 12 to 18 months in the context of only modest blood pressure and glucose-lowering effects, suggesting that clinical benefits were derived through nonhemodynamic, nonglycemic antiatherosclerotic mechanisms. Favorable effects, including a reduction in 3-point major adverse cardiovascular events (MACE) (26%), were also reported in the SUSTAIN-6 trial (Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) with the investigational GLP-1RA agent, semaglutide, effects driven primarily by a reduction in the risk for stroke, also over ≈12 to 18 months. 17, 18 Consistent with observations from the LEADER trial, semaglutide did not significantly modify the risk of hospitalization for HF. 17, 18 It is important to CV indicates cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; LV, left ventricular; PV, plasma volume; and SGLT2i, sodium glucose cotransporter 2 inhibitor.
note that the results of LEADER and SUSTAIN-6, which were obtained predominantly in patients who had T2D without HF, have been mirrored in real-world studies and meta-analyses examining GLP-1RA. 19, 20 Unfortunately, in recently hospitalized patients with advanced HF and reduced left ventricular ejection fraction (median 25%), dedicated studies with liraglutide were associated with overall neutral effects on cardiovascular death (at 180 days) and rehospitalization rates in comparison with placebo. These data suggest that GLP-1RA agents are safe in HF [21] [22] [23] [24] [25] and reduce risk factors for CVD (blood pressure, body weight), particularly among patients with T2D, but are unlikely to have direct beneficial effects on myocardial function in patients with HF who have advanced disease despite the expression of GLP-1 receptors in the heart.
In contrast with LEADER and SUSTAIN-6, SGLT2 inhibition with empagliflozin reduced the risk of hospitalization for HF in the EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). 26, 27 This cardiovascular safety trial randomly assigned patients with T2D and established CVD (≈10% with established HF) to 10 or 25 mg of empagliflozin once daily versus placebo in addition to standard of care. In comparison with placebo, participants treated with empagliflozin, pooled from both doses, had a 14% reduction in 3-point MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). The 35% reduction in the risk of hospitalization for HF emerged within several months, suggesting a role for acute effects on renal and systemic hemodynamic function or direct effects on the cardiovascular system (Figure 3 , see the Mechanism of Action section). Benefits on 3-point MACE were similar across estimated glomerular filtration rate (eGFR) subgroups down to an eGFR of 30 mL·min -1 ·1.73 m -2 , despite the fact that SGLT2 inhibitors are associated with less glucosuria as renal function declines. EMPA-REG OUT-COME also reported a 39% reduction in the composite renal end point, new-onset or worsening nephropathy (defined as incident macroalbuminuria, doubling of serum creatinine, eGFR ≤45 mL·min -1 ·1.73 m -2 , initiation of renal replacement therapy, or a renal disease-related death). 27 The results of 2 additional SGLT2 inhibitor cardiovascular safety trials, CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (Canagliflozin Cardiovascular Assessment Study-Renal) 28 have also been reported. In CANVAS, 4330 patients with T2D at high cardiovascular risk were randomly assigned 1:1:1 to 100 mg/d canagliflozin, 300 mg/d canagliflozin, or placebo for 2 years to evaluate 3-point MACE. 29 In CANVAS-R, the effect of canagliflozin for 2.5 years was evaluated in 5700 patients with T2D at elevated cardiovascular risk, with the primary outcome of kidney disease progression. 30 The secondary outcomes of CANVAS and CANVAS-R have been modified to prioritize vascular death, total mortality, and HF and to refine the outcomes addressing myocardial infarction and stroke. 30 Rather than evaluating separate effects of each dose of canagliflozin, the results of both studies and doses of canagliflozin were combined and reported as the CANVAS Program, with an overall HF prevalence of 14.4%. In the CANVAS Program with canagliflozin (n=10 142 patients with T2D), the primary end point, 3-point MACE, was significantly reduced, and the risk of hospitalization for HF was reduced by 33%. 31 From a renal perspective, the progression of albuminuria was reduced by 27%, and the composite outcome (sustained 40% reduction in eGFR, the need for renal-replacement therapy, or death from renal causes) was reduced by 40%. 31 The factors responsible for the acute beneficial effects on hospitalization for HF in EMPA-REG OUT-COME and the CANVAS Program are incompletely understood. The majority of patients (≈90%) in the EMPA-REG OUTCOME and CANVAS Program trials did not have HF at baseline, suggesting that the HF beneficial effects observed were attributable to Changes in peak oxygen consumption (Vo 2 ) (mL/kg/min) and minute ventilation (VE)/ carbon dioxide production (Vco 2 ) slope Not specified NCT02862067 TBD
ACEi indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BIA, bioelectrical impedance analysis; BNP, brain natriuretic peptide; CHF, congestive heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HbA1c, hemoglobin A1c; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVMi, left ventricular mass indexed; MACE, major adverse cardiovascular event; MI, myocardial infarction; NCT, National Clinical Trial; NTproBNP, N-terminal pro b-type natriuretic peptide; QoL, quality of life; RCT, randomized controlled trial; SBP, systolic blood pressure; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TBD, to be determined; and UAP, unstable angina pectoris. The results of the EMPA-REG OUTCOME trial have translated into the recognition of empagliflozin as a cardiovascular protective therapy for patients with T2D by the US Food and Drug Administration, the American College of Cardiology/American Heart Association, Diabetes Canada, and the European Society of Cardiology; similar perspectives may soon emerge for canagliflozin based on the CANVAS Program. Consistent with the observations in EMPA-REG OUTCOME and CANVAS, the broad impact of SGLT2 inhibition on cardiovascular outcomes has been observed in several real-world studies such as CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors), which reported significant benefits on mortality and hospitalization for HF risk with several SGLT2 inhibitor agents in an analysis of administrative data from 6 countries. 33 Separate analyses examining dapagliflozin versus other glucose-lowering therapies revealed similar beneficial cardiovascular effects, 34, 35 and an additional analysis demonstrated a 56% decreased risk of all-cause mortality and CVD with SGLT2 inhibition in a general practice cohort in Sweden. 36 
MECHANISMS OF ACTION OF SGLT2 INHIBITORS AND RELATIONSHIPS WITH CARDIOVASCULAR OUTCOMES
High-capacity, low-affinity SGLT2 are located in the renal proximal tubular epithelium and reabsorb filtered glucose ( Figure 1) . 37, 38 SGLT2 inhibition-related glycosuria results in an insulin-independent hemoglobin A1c (HbA1c) reduction of ≈0.7% to 1.0% in patients with T2D, and also body weight loss (≈2-3 kg) attributable to the induction of a negative caloric balance in patents with normal renal function 32 ( Figure 3 ). SGLT2 inhibition-induced glycosuria also mediates a uricosuric effect [39] [40] [41] via the GLUT9 transporter, 39 which may be cardioprotective, because increased plasma uric acid levels are associated with cardiovascular complications 42 and congestive HF. 43 Despite being safely used in T2D patients with CKD in clinical trials, canagliflozin dosing reductions are required for patients with eGFR of <60 and >45 mL·min 12 Similarly, glucosuriaassociated body weight loss was also unlikely to have accounted for the cardiovascular benefits with SGLT2 inhibition. Although <3.5% decreases in total body weight were observed in EMPA-REG OUTCOME and CANVAS Program, trials such as LOOK AHEAD (Action for Health in Diabetes) had no significant effects on lowering cardiovascular events over 10 years follow-up in overweight adults with T2D despite an average 6% loss of body weight. 44 Aside from the effects on glycemic control and weight loss, SGLT2s are responsible for ≈5% of sodium reabsorption at the proximal tubule under normal conditions. In the setting of chronic hyperglycemia, the capacity of SGLT2 in the kidney is increased leading to more pronounced effects on sodium homeostasis which decreases plasma volume and blood pressure with SGLT2 inhibition, as reviewed in more detail elsewhere. 32, [45] [46] [47] It is important to note that, for HF, SGLT2 inhibition-mediated effects on effective circulating volume contraction could reduce preload, thereby lowering ventricular filling pressure. Overall, the effects of SGLT2 inhibition on natriuresis and associated plasma volume contraction would be expected to reduce cardiac preload, whereas afterload reductions may occur through blood pressure and arterial stiffness lowering, thereby improving subendocardial blood flow.
In the kidney, SGLT2 inhibition-mediated proximal tubular natriuresis increases sodium delivery to the macula densa, which activates tubuloglomerular feedback, afferent vasoconstriction, and reduces glomerular pressure, as reviewed elsewhere. 40, 48, 49 These intrarenal hemodynamic effects may account for the 30% to 40% reduction in albuminuria observed with SGLT2 inhibitor agents, including empagliflozin, dapagliflozin, and canagliflozin. 26 The hemodynamic effects of SGLT2 inhibition occur even in the presence of renal dysfunction, despite the attenuated HbA1c-lowering effects in this setting. 50 Preservation of GFR might be of particular importance in patients with HF to avoid volume overload and complications arising from diuretic resistance (Figure 3) . Therefore, natriuresis mediated by SGLT2 inhibition is likely a major factor leading to cardiovascular and renoprotective effects observed with empagliflozin and canagliflozin, which appears to extend across CKD stages. 51 Whether other SGLT2 inhibitors will also demonstrate cardiac protection remains to be determined in large prospective cardiovascular safety studies (Table 1). 52 Despite the clinical relevance of maintaining sodium and water homeostasis in patients with HF, reliable measurements of changes in total body sodium in humans remains difficult because of the potential for multiple sodium reservoirs throughout the body. Recent studies suggest that tissues such as skin and muscle store sodium, and that sodium accumulation is associated with CVD. 53 In fact, the concentration of sodium in skin measured 24 Na-MRI correlates strongly with left ventricular mass and blood pressure in CKD, suggesting that it is a surrogate marker for volume-expanded states.
54 SGLT2 inhibition with dapagliflozin for 6 weeks significantly reduces skin sodium concentration measured by 24 Na-MRI in 59 patients with T2D, 55 suggesting that SGLT2 inhibition decreases both plasma volume and total body sodium content, which may protect against volume expansion and the risk of being hospitalized for HF.
Treatment of T2D patients with SGLT2 inhibitors typically reduces systolic blood pressure by 4 to 6 mm Hg and diastolic blood pressure by 1 to 2 mm Hg. 45, 46 In response to SGLT2 inhibition, similar magnitudes in systolic blood pressure reduction (≈2.7 mm Hg) have also been observed in healthy individuals without T2D. [56] [57] [58] [59] [60] Apart from natriuresis and osmotic diuresis, other mechanisms that might contribute to blood pressure lowering in response to SGLT2 inhibition include a decrease in arterial stiffness 61 and effects on endothelial function or vascular architecture. 62 Improvements in arterial stiffness with SGLT2 inhibition have been attributed in part to effective circulating volume contraction via mild diuretic effects and vascular smooth muscle relaxation. 56 Despite these antihypertensive effects, the risks of myocardial infarction, hospitalization for unstable angina, or stroke were not reduced in the EMPA-REG OUTCOME or CANVAS Program trials. This lack of effect on atherosclerosis-related end points argues against a major role for blood pressure lowering alone leading to cardiovascular benefits. Moreover, previous meta-analyses using other agents have suggested that modest blood pressure-lowering effects in EMPA-REG OUTCOME and the CANVAS Program were probably insufficient to account for the large impact on cardiovascular or renal end points. 63 Therefore, based on available evidence from these clinical trials, it seems highly unlikely that the reduction in cardiovascular risk with empagliflozin or canagliflozin can be attributed to glycemic control, blood pressure, or body weight reduction, suggesting the involvement of other SGLT2 inhibition-mediated mechanisms.
It is unclear whether SGLT2 inhibitors have direct effects on cardiomyocytes, because SGLT2 are not expressed in cardiac tissue in humans. 64 Recent preclinical studies in rat ventricular myocytes treated with empagliflozin, however, demonstrated direct SGLT2 inhibition-mediated cardiac effects by lowering myocardial intracellular sodium concentrations via inhibition of the myocardial Na + /H + exchanger flux with a secondary decrease in intracellular calcium and an increase in mitochondrial calcium. 65 Regulation of mitochondrial calcium concentrations by SGLT2 inhibition is of interest, because mitochondrial calcium is an activator of ATP synthesis and of antioxidant enzymatic pathways. 66, 67 In fact, increasing mitochondrial calcium concentrations prevents sudden death and overt HF in porcine models. 66 In addition, increases in myocardial intracellular sodium and calcium concentrations are early hallmarks and drivers of cardiovascular death and HF 68, 69 (Figure 3) . Further cardioprotective effects associated with SGLT2 inhibition may be derived through attenuating the prothrombotic milieu associated with hyperglycemia, which may be achieved through dapagliflozinmediated effects on neutrophil-derived S100 calciumbinding proteins A8/A9 (S100A8/A9), which interact with the receptor for advanced glycation end products. 70 In light of the rapid clinical benefits observed in EMPA-REG OUTCOME and the CANVAS Program, in particular, and animal models demonstrating protective effects on left ventricular mass and left ventricular enddiastolic diameter, 71 SGLT2 inhibition may have protective effects on cardiomyocytes or on inflammatory pathways in the cardiovascular system, an intriguing possibility that merits further investigation.
Beyond the effects on traditional cardiovascular risk factors or mitochondrial cardiomyocyte pathways is the possibility that the reduction in HF risk in EMPA-REG OUTCOME and in the CANVAS Program was related to metabolic substrate shifts from conventional fatty acids to ketone bodies. SGLT2 inhibition is associated with increased glucagon (possibly via direct pancreatic α-cell effects) and reduced insulin concentrations, thereby promoting the production of ketones such as β-hydroxybutyrate. 72 Ketones are freely taken up by the heart and can act as an efficient substrate for myocardial energy generation, as discussed elsewhere. [73] [74] [75] This metabolic substrate shift leads to improved energy use, potentially contributing to improved cardiac efficiency, contractility, and cardiovascular protection. In conjunction with increases in hematocrit leading to improved oxygen delivery to the heart, 76 SGLT2 inhibition may both increase oxygen supply to the heart and reduce cardiac oxygen demand, thereby improving cardiac function.
Given the acute nature of the HF benefit in EMPA-REG OUTCOME, 26 discussion around cardiovascular benefits have generally focused on either volume/hemodynamic pathways or on changes in energy use in the heart. However, it is important to recognize and highlight the possibility that both of these pathways may have protective and injurious potential. For example, natriuresis may be beneficial for reasons discussed above, but may also increase the risk of volume depletion and acute kidney injury, and promote neurohormonal activation. In EMPA-REG OUTCOME, empagliflozin was well tolerated hemodynamically and decreased the risk of acute kidney injury, possibly because of reduced loop diuretic use, which could help preserve renal function by the avoidance of volume depletion. 77 In the CANVAS Program, canagliflozin also did not increase the risk of acute kidney injury. It is fortunate that SGLT2 inhibition-mediated effects on the RAAS appear to be modest, [78] [79] [80] and the effects on sympathetic activity are neutral in patients without established HF. 81 Despite empirical evidence showing HF benefits in the EMPA-REG OUTCOME and CANVAS Program trials, the volume-related effects of SGLT2 inhibition in patients with HF are not yet fully understood. For example, in a pilot study involving 20 Japanese patients with T2D and HF, the addition of ipragliflozin to conventional loop or thiazide diuretics for 4 days decreased plasma natriuretic peptide levels without influencing plasma angiotensin II, aldosterone, or noradrenaline levels. 82 It is not known whether participants in EMPA-REG OUTCOME had HFrEF or HFpEF, because echocardiography was not performed at baseline. In a subsequent report, the EMPA-REG OUTCOME investigators explored HF outcomes from this trial and concluded that a decrease in HF hospitalization and cardiovascular death was consistent among patients with and without HF at baseline. Empagliflozin may therefore prevent HF decompensation, and incident HF, as well, in predisposed individuals. 77 The time course for the reduction in HF hospitalization risk with canagliflozin has not yet been reported in the CANVAS Program.
IMPACT OF SGLT2 INHIBITION ON CARDIAC STRUCTURE AND FUNCTION
Until ongoing small mechanistic studies and clinical trials are completed (Table 1) , the relative role(s) of SGLT2 inhibition on HF pathophysiology described above remains speculative. There are limited data evaluating whether SGLT2 inhibitors modify cardiac structure and function. In animals, SGLT2 inhibition reduces cardiac fibrosis, inflammation, and oxidative stress. 83 In several rodent models of T2D, SGLT2 inhibition improves diastolic function and left ventricular hypertrophy while simultaneously reducing myocardial fibrosis and expression of profibrotic/prohypertrophic proteins. [84] [85] [86] Verma et al 87 have also demonstrated cardioprotective effects in a zebrafish model of HF, suggesting conservation of cardiovascular protective effects across species. 87 In humans, an analysis of 10 patients with T2D (baseline HbA1c 7.3%) and established CVD who underwent transthoracic echocardiograms before and after 3 months of treatment with empagliflozin was recently reported. 88 The authors observed a significant reduction in left ventricular mass index, an established surrogate marker of cardiovascular risk, and improved diastolic function as determined by early lateral annular tissue Doppler velocity. Considering that SGLT2s are not expressed in the human myocardium, 89 it is difficult to reconcile whether and how SGLT2 inhibition could have direct effects on ventricular remodeling. It is possible that these SGLT2 inhibition-mediated effects on ventricular remodeling occur secondary to indirect effects on sodium and calcium entry into cardiomyocyte cellular compartments or via unknown effects in the heart. Further mechanistic studies are needed to better interpret the existing clinical data and to better define the effects of SGLT2 inhibition in cardiovascular tissue.
SGLT2 INHIBITION AND POTENTIAL SIDE EFFECTS
Although SGLT2 inhibition has emerged as a promising new cardiorenal protective therapy, it is important to recognize the potential adverse effects related to drugs in this class, including increased rates of genitourinary infections, postural hypotension, polyuria, diabetic ketoacidosis, acute kidney injury, and possible increased rates of bone fractures (Table 2) . 31, 32, [90] [91] [92] [93] The most commonly reported side effect attributable to glycosuria is genitourinary infections, mostly genital mycotic infections, but in some studies bacterial urinary tract infections as well. 32, [90] [91] [92] Less common but perhaps more important in the HF population in the context of concomitant diuretic use is the potential for volume depletion. Whether this hemodynamic effect will prove a serious risk for ill and elderly patients with comorbid medical conditions is unclear. Although the EMPA-REG OUTCOME trial did not report a specific approach to adjusting baseline diuretic agents, it is reasonable to be cautious when combining SGLT2 inhibitors with other diuretics, 94 as suggested elsewhere, 32 especially in patients with severe systolic dysfunction. Although acute kidney injury has been reported with SGLT2 inhibition, rates of acute kidney injury were less common in empagliflozin versus placebo-treated patients in the EMPA-REG OUTCOME trial, and similar trends were observed in the CANVAS Program. 27 This is reassuring, because 80% of patients in EMPA-REG OUTCOME were taking concomitant RAAS inhibitors, which also decrease intraglomerular pressure. 26 From a safety point of view, SGLT2 inhibitors should be part of sick-day T2D management strategies, and may need to be held in the context of nonsteroidal anti-inflammatory drug use or radiocontrast administration because of the potential for volume depletion and hemodynamic side effects. 94 In the CANVAS Program, patients treated with canagliflozin had a significantly higher risk of lower extremity amputations in comparison with the placebo group. 31 The increased risk of lower extremity amputations observed in CANVAS with canagliflozin has not been reported with dapagliflozin, empagliflozin, or other SGLT2 inhibitors. 95 Although the potential mechanisms responsible for differences in risk rates between members of this drug class for lower extremity amputations are not known, it may be relevant to recognize that canagliflozin has less SGLT2 selectivity than the other currently available SGLT2 inhibitors, and, as a consequence, this may induce more glucosuria. 96 Although it is not yet known if this translates to greater volume depletion with canagliflozin, a more pronounced rise in hematocrit and hemoconcentration could conceivably increase blood viscosity and hence tissue ischemia in the periphery. It is interesting to note that other diuretics that cause hemoconcentration may similarly increase amputation risk, although this has not been carefully studied. 97 In addition, canagliflozin, but not empagliflozin, impacts mitochondrial AMP-kinase activity, which is involved in mitochondrial energy pathways. 98 In animals, canagliflozin-associated AMP kinase activation was associated with inhibition of complex I of the respiratory chain, leading to increases in cellular AMP and ADP. Although it is not known if these pharmacological effects observed preclinically impact lower extremity perfusion, oxygenation, or energy delivery, these findings highlight the concept that SGLT2 inhibitors differ pharmacodynamically and thereby lead to differences in both benefit and adverse effect profiles. As an alternative explanation, data collection or reporting of amputations may have differed between the trials, leading to underreporting with other agents. Whereas further work is required to determine whether or not increased amputation risk occurs across the SGLT2 inhibitor drug class, a recent administrative data analysis using the Food and Drug Administration Adverse Event Reporting System reported a consistent increased risk of amputation with canagliflozin only, and no increased risk with either empagliflozin or dapagliflozin. 99 Whether the risk for amputation will be present in HF is unclear, but it should be explored further to determine if hypotension and peripheral hypoperfusion, both characteristic of HF, impact amputation risk further.
Notwithstanding the theoretical benefits around energy use described above, increased ketonemia in patients with diabetes mellitus taking SGLT2 inhibitors should raise concern for evolving diabetic ketoacidosis. Although not reported more frequently as an adverse effect in EMPA-REG OUTCOME or the CANVAS Program, the US Food and Drug Administration and European Medicines Agency have issued advisories about the potential risk of diabetic ketoacidosis with SGLT2 inhibitors. 100, 101 Fadini et al 102 recently published an analysis of the Food and Drug Administration Adverse Event Reporting System, which demonstrated a proportional reporting ratio of 7.9 (95% confidence interval, 7.5-8.4) for diabetic ketoacidosis in patients using SGLT2 inhibitors in comparison with those using other agents, with a higher risk in patients with type 1 diabetes mellitus. An increase in the risk of diabetic ketoacidosis was also observed by Fralick et al 93 in >76 000 commercially ). Acute kidney injury risk is not increased with SGLT2 inhibition in clinical trials (EMPA-REG OUTCOME, CANVAS Program) but has been reported in postmarketing data. Further work is required to determine the long-term significance of the eGFR dip, and to determine whether or not it is protective (ie, associated with reduced glomerular hypertension and proteinuria). insured patients with T2D in the United States taking SGLT2 inhibitors in comparison with those using dipeptidyl-peptidase 4 inhibitors (hazard ratio for diabetic ketoacidosis, 2.2; 95% confidence interval, 1.4-3.6). In contrast, a separate meta-analysis of completed clinical trials in >10 000 patients with T2D reported a reduction in risk of diabetic ketoacidosis, whereas a third administrative database analysis in >150 000 patients with T2D reported an overall neutral risk of diabetic ketoacidosis, highlighting that more data are needed to better understand this rare but potentially serious risk. [103] [104] [105] As a final comment, the CANVAS Program also reported an increased risk for bone fracture, an observation not yet reported with other agents in this drug class. Mechanistically, SGLT2 inhibition may exert adverse effects on bone physiology through increased concentrations of parathyroid hormone and fibroblast growth factor-23.
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The impact on bone fracture risk does not appear to exist across this drug class, because a recent meta-analysis by Tang et al 107 failed to broadly demonstrate bone fracture risk with SGLT2 inhibitor use. Whether bone fracture risk is of specific concern with SGLT2 inhibitors in HF is not known. Nevertheless, these agents should be used with caution in frail individuals who are at risk of falling, including those with hypotension.
ONGOING CARDIOVASCULAR TRIALS WITH SGLT2 INHIBITORS
In light of the emerging evidence for cardiovascular protection with SGLT2 inhibition, specifically empagliflozin and canagliflozin, clinical trials are currently underway to evaluate the impact of other SGLT2 inhibitors on primary cardiovascular outcomes in patients with T2D. 52 The DECLARE-TIMI58 trial (Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events) is a phase IIIb trial that is evaluating the effect of dapagliflozin (10 mg daily) versus placebo over 4.5 years on the composite 3-point MACE primary outcome in patients with T2D (Clinicaltrials.gov NCT01730534). 52 This trial is enrolling 17 150 patients with T2D and either known CVD (secondary prevention cohort) or at least 2 risk factors for CVD (primary prevention cohort). The impact of ertugliflozin on cardiovascular and renal end points is similarly being examined in the VERTIS study (Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease), although results are not anticipated until after 2020. 52 In addition to these trials, cardiovascular end points have been included as secondary end points in primary renal outcome trials. In the CREDENCE trial (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy Study), the objectives are to determine whether canagliflozin versus placebo for 5 years will reduce the primary composite end point of the study including end-stage kidney disease, doubling of serum creatinine, renal or cardiovascular death in patients with T2D with stage 2 or 3 CKD and macroalbuminuria (Clinicaltrials. gov NCT02065791). 52 The effects on progression of CKD or cardiovascular/renal death of dapagliflozin versus placebo as an addition to standard of care in 4000 patients with CKD are being examined in the 4-year follow-up DAPA-CKD study (Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease) (Clinicaltrials.gov NCT03036150). It is important to note that DAPA-CKD is recruiting patients with and without T2D to better define the role of SGLT2 inhibition as a renal protective therapy in the absence of hyperglycemia, perhaps through the natriuresis-related pathways discussed above. A second large CKD prevention trial with empagliflozin was announced on June 11, 2017, that will include patients with and without diabetic kidney disease, although no details are currently available. To date, no human studies have reported renal or cardiovascular effects in the setting of nondiabetic kidney disease. Accordingly, planned and ongoing nephropathy trials with empagliflozin and dapagliflozin in nondiabetic patients are based on the premise that volume-related and other nonglycemic mechanisms will extend to patients without diabetes mellitus, because glucose-lowering effects are unlikely to be responsible for end-organ protection. 108 In addition to studies such as DAPA-CKD in patients without diabetes mellitus that will evaluate primary renal end points, several large clinical trials have been announced that will investigate the impact of SGLT2 inhibition in patients who have HF with and without T2D. These trials include DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on Incidence of Worsening Heart failure or Cardiovascular Death in Patients with CHF), which is enrolling patients with HFrEF, and the EMPEROR trials (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure), which are including patients with HFrEF and HFpEF (Table 1 ). In addition, there are a number of ongoing smaller mechanistic studies in patients with T2D in this area that will better define SGLT2 inhibition-mediated mechanisms resulting in clinical HF benefits, including natriuresis, plasma volume contraction, and neurohormonal activation, as reviewed in Table 1 . As in the case of renal trials including individuals without T2D, the rationale for undertaking HF trials with SGLT2 inhibition in patients who do not have T2D is to take advantage of glucose-independent cardiorenal protective pathways in response to SGLT2 inhibition. Once complete, these ongoing studies will help elucidate the complex pharmacodynamic effects of SGLT2 inhibition on CVD in patients with and without T2D. CONCLUSIONS SGLT2 inhibition may emerge as an effective and safe adjunctive therapy for HF that promotes hemodynamic stability and helps correct volume overload, while avoiding the risks of volume depletion, independent of effects on hyperglycemia. Nevertheless, the mechanisms responsible for the acute cardioprotective effects of SGLT2 inhibition, such as sodium and water homeostasis and plasma volume regulation, must be examined in diverse populations, including in patients with and without T2D, and in those with HFpEF and HFrEF. Furthermore, the therapeutic landscape will continue to evolve with the use of new agents that impact circulating volume, such endothelin-1A receptor antagonists (sodium retention) and angiotensin receptor-neprilysin inhibitors (natriuresis). The diabetes research community will also need to focus on understanding how these various agents interact in combination, both in terms of blood pressure, albuminuria, and cardiorenal benefits, and around the potential for adverse effects. 109 In light of EMPA-REG OUTCOME, the CANVAS Program, and studies with GLP-1RA agents, the management of patients with T2D and existing CVD is evolving. Because clinicians now have access to effective therapies to prevent cardiorenal events, future trials need to consider whether the demonstration of noninferiority is sufficient, or whether superiority should be targeted, especially for HF events. In addition, although existing trial evidence has demonstrated unexpectedly robust protection in patients with existing complications, it remains to be determined whether these agents will be similarly effective as primary prevention strategies. 
SOURCES OF FUNDING
DISCLOSURES
Dr Udell has received consulting fees or speaking honoraria from Amgen, Janssen, Merck, Novartis, Sanofi Pasteur and Boehringer Ingelheim; and grant support from Novartis. Dr Lovshin receives honorarium and/or consulting fees from Novo Nordisk, Merck, Eli Lilly and Co., and AstraZeneca. Dr Lovshin has received grants from Sanofi and Merck Canada. Dr Cherney receives operating funding from Boehringer Ingelheim, Janssen, AstraZeneca, and Merck, and has received consulting fees or speaking honoraria from Boehringer Ingelheim, Janssen, AstraZeneca, Merck, Mitsubishi-Tanabe, Sanofi, and Abbvie. Dr Bjornstad receives consulting fees from Boehringer Ingelheim.
